Back to top
more

Voyager Therapeutics (VYGR)

(Delayed Data from NSDQ)

$3.21 USD

3.21
1,457,884

+0.25 (8.45%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $3.22 +0.01 (0.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Voyager Therapeutics (VYGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Sage Therapeutics to Reduce Workforce by 33%, Stock Down

by Zacks Equity Research

SAGE announces a portfolio reprioritization plan to focus on the launch of the depression drug Zurzuvae and other pipeline developments. Stock falls in after-hours trading.

Zacks Equity Research

GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review

by Zacks Equity Research

The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.

Zacks Equity Research

SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies

by Zacks Equity Research

Sanofi inks an agreement with Orano Med to develop next-generation radioligand medicines to treat rare cancers.

Zacks Equity Research

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

by Zacks Equity Research

The FDA bestows an orphan drug designation to Immuneering's lead candidate, IMM-1-104, for the treatment of pancreatic cancer. Shares rise.

Zacks Equity Research

Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Bicycle Therapeutics (BCYC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?

by Zacks Equity Research

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Novartis to License VYGR's Capsid for Gene Therapy in Neurology

by Zacks Equity Research

NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 52.63% and 156.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 54.55% and 88.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 21.48% and 85.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 26.17% and 10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates

by Zacks Equity Research

Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.

Zacks Equity Research

Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat

by Zacks Equity Research

Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024.

Zacks Equity Research

Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.

Zacks Equity Research

Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.

Zacks Equity Research

Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research

Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.

Zacks Equity Research

Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates

by Zacks Equity Research

Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.

Zacks Equity Research

Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Amarin (AMRN) posts better-than-expected first-quarter 2024 results. Vascepa's sales in the United States continue to be hurt by generic competition.

Zacks Equity Research

Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short

by Zacks Equity Research

Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.

Zacks Equity Research

New Strong Buy Stocks for May 1st

by Zacks Equity Research

EC, SKX, BVN, VYGR and WU have been added to the Zacks Rank #1 (Strong Buy) List on May 1, 2023.

Zacks Equity Research

Novavax (NVAX) Surges 8.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More

by Zacks Equity Research

Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.

Zacks Equity Research

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis

by Zacks Equity Research

Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 13.56% and 142.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?